{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:04:20Z","timestamp":1777111460810,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd007303","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,7,8]],"date-time":"2009-07-08T00:00:00Z","timestamp":1247011200000}}],"reference-count":336,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007303.pub2","type":"journal-article","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T07:10:26Z","timestamp":1246605026000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data"],"prefix":"10.1002","volume":"2010","author":[{"given":"Julia","family":"Bohlius","sequence":"first","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Schmidlin","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Brillant","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"Insitute of Medical Biometry and Medical Informatics; German Cochrane Centre; University Medical Center Freiburg Stefan-Meier-Str. 26 Freiburg Germany D-79104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Trelle","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Seidenfeld","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology; Department of Cancer Policy and Clinical Affairs; 1900 Duke Street, Suite 200 Alexandria VA USA 22314"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Zwahlen","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike J","family":"Clarke","sequence":"additional","affiliation":[{"name":"UK Cochrane Centre; National Institute for Health Research Summertown Pavilion, Middle Way Oxford UK OX2 7LG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Weingart","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Kluge","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Piper","sequence":"additional","affiliation":[{"name":"Blue Cross and Blue Shield Association; Technology Evaluation Center; 225 N Michigan Avenue Chicago IL USA 60501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryann","family":"Napoli","sequence":"additional","affiliation":[{"name":"Center for Medical Consumers; 130 Macdougal Street New York USA 10012"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Rades","sequence":"additional","affiliation":[{"name":"University Hospital; Department of Radiation Oncology; L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Steensma","sequence":"additional","affiliation":[{"name":"Mayo Clinic; 200 First St. S.W. Rochester MN USA MN 55905"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[{"name":"Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida; Professor of Medicine and Oncology, H. Lee Moffitt Cancer Center; USF Health Clinical Research, 12901 Bruce B. Downs Boulevard, MDC02 Tampa Florida USA 33612"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin F","family":"Fey","sequence":"additional","affiliation":[{"name":"University and Inselspital Bern; Department of Medical Oncology; Effingerstra\u00dfe 102 Bern Switzerland 3010"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard; 28 rue Laennec Lyon France 69008"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Moebus","sequence":"additional","affiliation":[{"name":"Academic Hospital Frankfurt am Main H\u00f6chst; Department of Gynecology; Gotenstra\u00dfe 6-8 Frankfurt a.M. Germany 65929"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Toronto; Odette Sunnybrook Cancer Centre; Roxborough Street W Toronto Ontario Canada M5R 1V1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[{"name":"Helios Hospital Berlin-Buch; Clinic for Gynaecology; Schwanebecker Chaussee 50 Berlin Germany 13125"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg; German Cochrane Center; Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine; Institute of Social Medicine; Finkenhubelweg 11 Bern Switzerland 3012"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"10.1002\/14651858.CD007303.pub2-BIB0001|cit1","unstructured":"Aapro M Barnadas A Leonard RC Marangolo M Untch M Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of the BRAVE trial Breast Cancer Research and Treatment 2006 abstract 6095"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2007.11.5378","article-title":"Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and\/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) Study","volume":"26","author":"Aapro","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007303.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(05)80281-3","article-title":"Erythropoietin for anemia in cancer patients","volume":"29a","author":"Abels","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007303.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000204780","article-title":"Recombinant Human Erythropoietin in the Treatment of the Anaemia of Cancer","volume":"87","author":"Abels","year":"1992","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.bjc.6600801","article-title":"Impact of epoetin beta on quality of life in patients with malignant disease","volume":"88","author":"Boogaerts","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0008|cit7","unstructured":"Coiffier B Epoetin beta (Neorecormon\u00a9) improves quality of life in cancer-associated anaemia to a similar degree in patients with lymphoid malignancies or solid tumours Proceedings of the 8th Congress of the European Haematology Association 2003 abstract 0153"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007303.pub2-BIB0007|cit8","first-page":"abstract 194","article-title":"Impact of epoetin beta versus standard care on quality of life in patients with malignant disease","volume":"2","author":"Coiffier","year":"2001","journal-title":"Proceedings of the 6th Congress of the European Haematology Association"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jnci\/85.10.801","article-title":"Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy","volume":"85","author":"Case","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0012|cit12","unstructured":"Luksenburg H Weir A Wager R P-174 in: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee Rockville (MD), USA, 2004"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1995.tb08374.x","article-title":"Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin","volume":"89","author":"Pangalis","year":"1995","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","article-title":"Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"23","author":"Chang","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Charu V Belani CP Gill AN Bhatt M Ben Jacob A Tomita D A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer Annual Meeting Proceedings of the American Society of Clinical Oncology 2004 abstract 8084","DOI":"10.1200\/jco.2004.22.90140.8084"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1634\/theoncologist.12-6-727","article-title":"Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial","volume":"12","author":"Charu","year":"2007","journal-title":"Oncologist"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007303.pub2-BIB0017|cit17","first-page":"14","article-title":"Improvements in fatigue are associated with early treatment with darbepoetin alfa every 3 weeks in anemic patients receiving chemotherapy","volume":"3","author":"Charu","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammacco","year":"1998","journal-title":"International Journal of Clinical and Laboratory Research"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0020|cit20","unstructured":"Debus J Hindermann S Morr H Mezger J Sebastian M Angermund R Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC - Interim results 27th Congress of the German Cancer Society Berlin, Germany, 2006. German Medical Science 2006 abstract PO147"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Debus J Hindermann S Morr H Mezger J Sebastian M Angermund R Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC - Interim results Lung Cancer 2005 S57","DOI":"10.1016\/S0169-5002(05)81040-2"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0022|cit22","unstructured":"Luksenburg H Weir A Wager R EPO-GBR-7: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0023|cit23","unstructured":"EPO-GER-20 Prospective, randomized, controlled, open phase-IV study on the treatment of small cell lung cancer (SCLC) in the extensive disease (ED) stage per VALGB classification with doxorubicin, cyclophosphamide, etoposide (ACE regimen) unpublished: Angermund R, Janssen-Cilag, personal communication"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0024|cit24","unstructured":"Luksenburg H Weir A Wager R EPO-INT-1: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0025|cit25","unstructured":"Luksenburg H Weir A Wager R EPO-INT-3: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee Rockville (MD), USA, 2004"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1634\/theoncologist.2007-0241","article-title":"Treating anemia of cancer with every-4-week darbepoetin alfa: Final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study","volume":"13","author":"Gordon","year":"2008","journal-title":"The Oncologist"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Gordon DH Nichols G Ben Jacob A Lam H Lillie T Miller C Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-Blind, placebo-controlled study in cancer patients not receiving chemotherapy and\/or radiotherapy Blood 2006 abstract 1304","DOI":"10.1182\/blood.V108.11.1304.1304"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Goss G Feld R Bezjak A Perry G Melosky B Smith C Impact of maintaining Hb with epoetin alfa on time to progression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients Lung cancer 2005 S53","DOI":"10.1016\/S0169-5002(05)80288-0"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0029|cit29","unstructured":"Luksenburg H Weir A Wager R EPO-CAN-15: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"issue":"36","key":"10.1002\/14651858.CD007303.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1200\/JCO.2005.01.8507","article-title":"Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Grote","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0031|cit31","unstructured":"Luksenburg H Weir A Wager R N93-004: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0032|cit32","unstructured":"20000161 Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2007"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0034|cit34","unstructured":"Hedenus M Brandberg Y Molostova V Iosova G Abdulkadyrov K Messinger D Efficacy of epoetin beta in treating the anaemia of cancer in patients with haematological malignancies Proceedings of the 6th Congress of the European Haematology Association 2001 abstract 190"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0036|cit36","first-page":"292","article-title":"Erythropoietin in patients with head and neck carcinomas?","volume":"83","author":"Schipper","year":"2004","journal-title":"Laryngorhinootologie"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"2 (Suppl 3)","key":"10.1002\/14651858.CD007303.pub2-BIB0038|cit38","first-page":"21","article-title":"Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies","volume":"21","author":"Henry","year":"1994","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0039|cit39","first-page":"252","article-title":"Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients Receiving Cisplatin Chemotherapy","volume":"1","author":"Henry","year":"1995","journal-title":"The Cancer Journal from Scientific American"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0040|cit40","unstructured":"Huddart RA Welch RS Chan S Perren T Atkinson R A prospective randomised comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy Annals of Oncology 2002 177"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Kotasek D Albertsson M Mackey J Darbepoetin Alfa 980291 Study Group Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors Proceedings of the American Society of Clinical Oncology 2002 356a","DOI":"10.1016\/S0959-8049(02)80431-2"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0042|cit42","unstructured":"Kotasek D Albertsson M Mackey J Steger G Rossi G O'Byne J Once per cycle dosing of darbepoetin alfa is feasible in anemic cancer patients receiving chemotherapy Annals of Oncology 2002 170"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0043|cit43","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD007303.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0046|cit45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncology"},{"issue":"25","key":"10.1002\/14651858.CD007303.pub2-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"3 Suppl 8","key":"10.1002\/14651858.CD007303.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/sonc.2002.33534","article-title":"Age, anemia, and fatigue","volume":"29","author":"Aapro","year":"2002","journal-title":"Seminars in Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1023\/A:1026116426494","article-title":"Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients","volume":"12","author":"Fairclough","year":"2003","journal-title":"Quality of Life Research"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0055|cit51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000061296","article-title":"Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy","volume":"37","author":"Littlewood","year":"2002","journal-title":"Frontiers of radiation therapy and oncology"},{"issue":"11","key":"10.1002\/14651858.CD007303.pub2-BIB0051|cit52","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0052|cit53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(02)00827-6","article-title":"Erythropoietin improves quality of life","volume":"3","author":"Littlewood","year":"2002","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0053|cit54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpainsymman.2005.08.013","article-title":"Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies","volume":"31","author":"Littlewood","year":"2006","journal-title":"Journal of Pain & Symptom Management"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0054|cit55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hon.722","article-title":"Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy","volume":"21","author":"Littlewood","year":"2003","journal-title":"Hematological Oncology"},{"issue":"16","key":"10.1002\/14651858.CD007303.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200321160-00002","article-title":"Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer","volume":"21","author":"Martin","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007303.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2004.06.031","article-title":"Definitive radiotherapy +\/- erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03","volume":"60","author":"Machtay","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology and Physics"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2007.04.063","article-title":"Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)","volume":"69","author":"Machtay","year":"2007","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Milroy R Scagliotti G van den Berg PM Galanis NE G\u00f3mez RG Greil R Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients Lung Cancer 2003 S74","DOI":"10.1016\/S0169-5002(03)91911-8"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0060|cit60","unstructured":"Moebus V Bastert G Kreienberg R Eidtmann H Cierna M Untch M Epoetin Alpha Prevents Anemia and Transfusions of RBCS in Patients Receiving Dose-Dense Sequential Chemotherapy Proceedings of the American Society of Clinical Oncology 2001 abstract 36"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Moebus V Lueck H Thomssen C Harbeck N Nitz U Kreienberg R The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) Journal of Clinical Oncology 2007 569","DOI":"10.1200\/jco.2007.25.18_suppl.569"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Moebus V Untch M du Bois A Lueck HJ Thomssen C Kuhn W Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (>= 4 +LN). First results of an AGO-trial Journal of Clinical Oncology 2004 abstract 513","DOI":"10.1200\/jco.2004.22.90140.513"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Untch M Jackisch C Lenhard MS du Bois A Lueck HJ Thomssen C Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) Journal of Clinical Oncology 2005 613","DOI":"10.1200\/jco.2005.23.16_suppl.613"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"O'Shaugnessy J Vukelja S Savin M Holmes FA Jones M Royall D Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy: a double-blind, randomized, placebo-controlled trial Proceedings of the American Society of Clinical Oncology 2002 abstract 1449","DOI":"10.3816\/CBC.2002.s.022"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0065|cit65","unstructured":"O'Shaugnessy J Vukelja S Savin M Holmes FA Jones M Royall D Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data Proceedings from the 25th Annual Breast Cancer Symposium 2002 abstract: 550"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3816\/CBC.2005.n.002","article-title":"Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy","volume":"5","author":"O'Shaugnessy","year":"2005","journal-title":"Clinical Breast Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0067|cit67","unstructured":"OBE\/EPO-INT-03 A randomized comparison of the effect of maintaining haemoglobin levels with weekly epoetin alfa or with conventional anaemia management in subjects with Multiple Myeloma undergoing chemotherapy (EMMY) unpublished: Murphy R, Janssen-Cilag, personal communication"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0068|cit68","unstructured":"Oberhoff C Krumeich B Winkler UH Hoffmann O Schindler AE Recombinant human erythropoietin (epoetin beta) in the treatment of chemotherapy - associated anaemia: effects on blood coagulation and fibrinolysis in patients with gynecological malignancies Annals of Hematology 2000 B16"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1008296622469","article-title":"Recombinant human erythropoietin in the treatment of chemotherapy- induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study","volume":"9","author":"Oberhoff","year":"1998","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/s-2005-858478","article-title":"Prevention and therapy of anemia in tumor patients with Epoetin beta (NeoRecormon)","volume":"26","author":"Oberhoff","year":"2005","journal-title":"Tumor Diagnostik und Therapie"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-\u00df on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0074|cit74","unstructured":"Amgen Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer Amgen Thousand Oaks, CA, 2007"},{"issue":"14","key":"10.1002\/14651858.CD007303.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2007.15.0748","article-title":"Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide","volume":"26","author":"Pirker","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0076|cit76","unstructured":"Pronzato P Cortesi E van der Rijt C Moreno-Nogueria A Raimundo D Ostler P Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group) Annals of Oncology 2002 168"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0077|cit77","unstructured":"Quirt I Micucci S Moran LA Pater J Browman G The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled clinical trial Blood 1996 347a, abstract 1378"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I Dussart S Goillot C Mayeur D Debourdeau P Ghesquieres H A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin {alpha}: a prospective randomized controlled trial of the ELYPSE study group Annals of Oncology 2009","DOI":"10.1093\/annonc\/mdn750"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD007303.pub2-BIB0079|cit79","first-page":"ix294","article-title":"ELYPSE 4: A prospective randomized trial comparing Epo A in primary prophylaxis of severe anemia requiring red cells transfusion in high risk patients","volume":"17","author":"Ray-Coquard","year":"2006","journal-title":"Annals of Oncology"},{"issue":"6 Suppl 4","key":"10.1002\/14651858.CD007303.pub2-BIB0080|cit80","first-page":"10","article-title":"Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy","volume":"3","author":"Hinds","year":"2005","journal-title":"Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Razzouk BI Hockenberry M Hinds PS Feusner J Rackoff W Hord JD Influence of hemoglobin response to epoetin alfa on quality-of-life in anemic children with cancer receiving myelosuppressive chemotherapy Blood 2004 abstract 221","DOI":"10.1182\/blood.V104.11.2218.2218"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Razzouk BI Hockenberry M Hinds PS Rackoff W Hord JD A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy Journal of Clinical Oncology 2004 abstract 8527","DOI":"10.1200\/jco.2004.22.90140.8527"},{"issue":"22","key":"10.1002\/14651858.CD007303.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.2005.03.4371","article-title":"Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy","volume":"24","author":"Razzouk","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0084|cit84","unstructured":"Rose E Rai K Revicki D Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO) Blood 1994 526a"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Savonije J Van Groeningen C Van Bochove A Pinedo H Giaccone G Early intervention with epoetin-alfa during platinum-based chemotherapy Journal of Clinical Oncology 2004 abstract 8111","DOI":"10.1200\/jco.2004.22.90140.8111"},{"issue":"11","key":"10.1002\/14651858.CD007303.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ejca.2005.03.024","article-title":"Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial","volume":"41","author":"Savonije","year":"2005","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1634\/theoncologist.11-2-197","article-title":"Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data","volume":"11","author":"Savonije","year":"2006","journal-title":"The oncologist"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0088|cit88","unstructured":"20010103 Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drugs Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2007"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0089|cit89","unstructured":"Glaspy J Smith RE Aapro M Ludwig H Pinter T Smakal M Results from a phase 3 randomized, double blind, placebo controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy Haematologica 2007 136"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","volume":"26","author":"Smith","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Strauss H Haendgen G Dunst.J Koelbl H Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer Proceedings of the American Society of Clinical Oncology 2003 abstract 5121","DOI":"10.1200\/jco.2005.23.16_suppl.5121"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007303.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1525-1438.2007.01032.x","article-title":"Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer","volume":"18","author":"Strauss","year":"2008","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Taylor K Ganly P Charu V DiBenedetto J Kracht K Rossi G Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia Blood 2005 abstract 3556","DOI":"10.1182\/blood.V106.11.3556.3556"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Reed N Rhan S Hayward C Burger H Ten Bokkel Huinink W Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy Proceedings of the American Society of Clinical Oncology 2003 abstract 5102","DOI":"10.1200\/jco.2005.23.16_suppl.5102"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","article-title":"Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy","volume":"15","author":"Bokkel Huinink","year":"1998","journal-title":"Medical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1200\/JCO.1995.13.7.1623","article-title":"Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer","volume":"13","author":"Campos","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"3-4","key":"10.1002\/14651858.CD007303.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjc.6690369","article-title":"Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer","volume":"80","author":"Thatcher","year":"1999","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0098|cit98","unstructured":"Thomas H McAdam KF Thomas RJ Joffe JK Sugden EM Awwad ST Early intervention with epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy Annals of Oncology 2002 177"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0099|cit99","unstructured":"Luksenburg H Weir A Wager R GOG-191: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the treatment of Anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2007.10.011","article-title":"Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0\u00a0g\/dL with erythropoietin vs above 10.0\u00a0g\/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Untch M Fascing PA Bauernfeind I Conrad U Camara O Fett W PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin\/cyclophosphamide followed by paclitaxel +\/- darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery Journal of Clinical Oncology 2008 abstract 517","DOI":"10.1200\/jco.2008.26.15_suppl.517"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Vadhan-Raj S Skibber JM Crane C Buesos-Ramos CE Rodriguez-Bigas MA Feig BW Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT\/RT) followed by surgery: early termination of the trial due to increased incidence of thromboembolic events (TEE) Blood 2004 797a, abstract 2915","DOI":"10.1182\/blood.V104.11.2915.2915"},{"issue":"9 Suppl 10","key":"10.1002\/14651858.CD007303.pub2-BIB0103|cit103","first-page":"117","article-title":"Psychological outcomes associated with anemia-related fatigue in cancer patients","volume":"16","author":"Kallich","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Pirker R Vansteenkiste J Gateley J Yates P Colowick A Musil J A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer Proceedings of the American Society of Clinical Oncology 2001 abstract 1572","DOI":"10.1016\/S0959-8049(01)81473-8"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cncr.11463","article-title":"The relationship between psychologic distress and cancer-related fatigue","volume":"98","author":"Tchekmedyian","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0106|cit106","unstructured":"Tchekmedyian S Glaspy J Colowick A Tomita D Rossi G Effect of darbepoetin alfa and recombinant human erythropoietin (rHuEPO) on early hemoglobin (Hb) changes in anemic cancer patients (pts) Annals of Oncology 2002 184"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"10 Suppl 11","key":"10.1002\/14651858.CD007303.pub2-BIB0108|cit108","first-page":"45","article-title":"Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations","volume":"16","author":"Vansteenkiste","year":"2002","journal-title":"Oncology (Huntingt)"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0109|cit109","first-page":"253","article-title":"Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline","volume":"12","author":"Vansteenkiste","year":"2004","journal-title":"Supportive Care in Cancer"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6603004","article-title":"Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial","volume":"94","author":"Wilkinson","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Dicato M Vercammen E Liu KL Xiu LX Bowers P Relationship of body weight to efficacy of a fixed-dose regimen of epoetin alfa vs placebo in anemic cancer patients Haematologica 2005 abstract 0077","DOI":"10.1200\/jco.2005.23.16_suppl.8192"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","article-title":"Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy","volume":"23","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0113|cit113","unstructured":"Luksenburg H Weir A Wager R EPO-CAN-20: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the treatment of anemia associated with cancer chemotherapy Oncologic Drugs Advisory Committee, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville (MD), USA, 2004"},{"issue":"9","key":"10.1002\/14651858.CD007303.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10245330701521572","article-title":"Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0116|cit116","first-page":"abstract 832P","article-title":"A randomized comparison of rHuEPO with darbepoetin for cancer related anemia","volume":"15 Suppl 3","author":"Alexopoulos","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Antonadou D Cardamakis E Puglisi M Malamos N Throuvalas N Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study European Journal of Cancer 2001 S144","DOI":"10.1016\/S0959-8049(01)81022-4"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0118|cit118","first-page":"127","article-title":"Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study","volume":"8","author":"Aravantinos","year":"2003","journal-title":"Journal of the Balkan Union of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Aziz K Hashem T Mobarek N Bary N Ghoneimy I Haddad S Does Recombinant Human Erythropoietin Improve the Outcome of Radiation Therapy in Head and Neck Cancer Patients Proceedings of the American Society for Therapeutic Radiology and Oncology 2001 abstract 2274","DOI":"10.1016\/S0360-3016(01)02503-2"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000067766","article-title":"Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group","volume":"64","author":"Bamias","year":"2003","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0122|cit122","doi-asserted-by":"crossref","unstructured":"Beggs VL Disalvo WM Meyer LP Gragnev KH Gibson JJ Hoopes PJ Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unresectable non-small cell lung cancer (NSCLC) Proceedings of the American Society of Clinical Oncology 2003 abstract 2948","DOI":"10.1016\/S0169-5002(03)92207-0"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0609.1997.tb01665.x","article-title":"Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group","volume":"58","author":"Bessho","year":"1997","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Bindi M Montemaggi P Sabatino M Paolelli L Petrioli R Morelli R Reticulocytes can represent an early indicator of the erythropoietic response to Darbepoetin alfa in the anemia by chemotherapy Journal of Clinical Oncology 2004 786, abstract 8245","DOI":"10.1200\/jco.2004.22.90140.8245"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0125|cit125","unstructured":"Blayney D Fesen M Mirtsching BC Katz D Tomita D Every-2-Week Darbepoetin Alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: A stratified analysis by tumor type Blood 2003 abstract 3779"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0126|cit126","unstructured":"Blohmer JU Petry K Kolben M Kimmig R Boehmer D Wuerschmidt J Adjuvant sequential chemo-radiotherapy with vs. without erythropoietin in high-risk patients with carcinoma of the cervix Proceedings of the American Society of Clinical Oncology 2001 abstract: 823"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0127|cit127","first-page":"abstract 447PD","article-title":"Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study","volume":"15 (Suppl 3)","author":"Blohmer","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0128|cit128","unstructured":"Blohmer U Wurschmidt U Petry G Weise J Sehouli J Kimmig R 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer Proceedings of the American Society of Clinical Oncology 2003 abstract 1789"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/MO:22:2:161","article-title":"Anemia in cervical cancer patients: implications for iron supplementation therapy","volume":"22","author":"Candelaria","year":"2005","journal-title":"Medical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djj053","article-title":"Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"98","author":"Canon","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Canon JL Vansteenkiste J Bodoky G Mateos MV Bastit L Ferreira I Results of a randomised, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks for the treatment of anaemia in patients receiving multicycle chemotherapy Haematologica 2005 abstract 471","DOI":"10.1200\/jco.2005.23.16_suppl.lba8284"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0132|cit132","doi-asserted-by":"crossref","unstructured":"Carabantes FJ Alonso CJ Rius F Benavides M Hebrero ML Garcia S Epoetin alfa (EPO) prevents anaemia and improves quality of life (QOL) in cancer patients (PTS) undergoing platinum-based chemotherapy European Journal of Cancer 1999 abstract 1482","DOI":"10.1016\/S0959-8049(99)81897-8"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0133|cit133","unstructured":"Carabantes FJ Benavides M Trujillo R Cobo M Hebrero ML Garcia S Epoetin alfa in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy (CT). A prospective randomized study Proceedings of the American Society of Clinical Oncology 1999 abstract 2303"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0135|cit135","unstructured":"Casadevall N Lepage E Durieux P Dubois S Dreyfus F Quarre MC Erythropoietin (RHUEPO) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomised trial with impact on quality of life and costs The Hematology Journal 2001 abstract 687"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","article-title":"Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo","volume":"12","author":"Cascinu","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0138|cit138","unstructured":"Cazzola M Coiffier B Kloczko J Spika I Once weekly NeoRecormon\u00ae (epoetin beta) for the treatment of anemia associated with lymphoproliferative malignancies: results of the NOW (NeoRecormon\u00ae once weekly) study Hematology Journal 2002 abstract 0182"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0936-6555(05)80622-3","article-title":"Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy","volume":"7","author":"Chan","year":"1995","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0140|cit140","doi-asserted-by":"crossref","unstructured":"Charu V Belani CP Gill AN Bhatt M Ben Jacob A Tomita D A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer Annual Meeting Proceedings of the American Society of Clinical Oncology 2004 abstract 8084","DOI":"10.1200\/jco.2004.22.90140.8084"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.12-10-1253","article-title":"A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia","volume":"12","author":"Charu","year":"2007","journal-title":"Oncologist"},{"issue":"9","key":"10.1002\/14651858.CD007303.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/ASO.2005.06.031","article-title":"Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study","volume":"12","author":"Christodoulakis","year":"2005","journal-title":"Annals of Surgical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0143|cit143","doi-asserted-by":"crossref","unstructured":"Crawford J Blackwell S Shoemaker D Pupa MR Sparrow T Herndon J Prevention of chemotherapy-related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support Lung Cancer 1997 abstract 796","DOI":"10.1016\/S0169-5002(97)80173-0"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0144|cit144","first-page":"628, abstract 2","article-title":"Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy","volume":"22","author":"Crawford","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JTO.0b013e318031cd9a","article-title":"A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy","volume":"2","author":"Crawford","year":"2007","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0146|cit146","first-page":"5374","article-title":"Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study","volume":"58","author":"Daneryd","year":"1998","journal-title":"Cancer Research"},{"issue":"20","key":"10.1002\/14651858.CD007303.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1158\/1078-0432.CCR-04-0373","article-title":"Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients","volume":"10","author":"Lindholm","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12032-007-9001-7","article-title":"Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care","volume":"25","author":"Lonnroth","year":"2008","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Dannemann B Wacholtz M Lau H Cheung W Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in cancer patients with anemia receiving cyclic chemotherapy Journal of Clinical Oncology 2004 775, abstract 8203","DOI":"10.1200\/jco.2004.22.90140.8203"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.1997.15.7.2715","article-title":"Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia","volume":"15","author":"Mastro","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1362::AID-CNCR36>3.0.CO;2-T","article-title":"Erythropoietin Reduces Anemia and Transfusions","volume":"86","author":"Dunphy","year":"1999","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Elsaid A Farouk M Significance of anemia and role of erythropoietin in radiation induced mucositis in head and neck cancer patients International Journal of Radiation Oncology Biology Physics 2001 368","DOI":"10.1016\/S0360-3016(01)02504-4"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/pbc.20685","article-title":"Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer","volume":"47","author":"Freeman III","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma","volume":"155","author":"Garton","year":"1995","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0155|cit155","first-page":"341","article-title":"Subcutaneous recombinant human erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer","volume":"1","author":"Gebbia","year":"1992","journal-title":"International Journal of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.bjc.6600465","article-title":"Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy","volume":"87","author":"Glaspy","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"10 Suppl 11","key":"10.1002\/14651858.CD007303.pub2-BIB0157|cit157","first-page":"23","article-title":"Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy","volume":"16","author":"Glaspy","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/cncr.11186","article-title":"A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease","volume":"97","author":"Glaspy","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejca.2005.01.021","article-title":"Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa","volume":"41","author":"Glaspy","year":"2005","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0160|cit160","unstructured":"Glaspy J Jadeja J Justice G Fleishman A Rossi G Colowick A Optimizing the management of anemia in patients with cancer: a randomized, active-controlled, study investigating the dosing of darbepoetin alfa Hematology Journal 2002 abstract 0109"},{"issue":"15","key":"10.1002\/14651858.CD007303.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1200\/JCO.2005.03.8570","article-title":"Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial","volume":"24","author":"Glaspy","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1998.16.2.434","article-title":"Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer","volume":"16","author":"Glimelius","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00277-003-0695-0","article-title":"Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy - results of a randomized trial","volume":"82","author":"Glossmann","year":"2003","journal-title":"Annals of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0164|cit164","first-page":"1289","article-title":"Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy","volume":"10","author":"Granetto","year":"2003","journal-title":"Oncology Reports"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","article-title":"Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies","volume":"119","author":"Hedenus","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0167|cit167","doi-asserted-by":"crossref","unstructured":"Hedenus M Nasman P Epoetin beta with intravenous iron results in overall cost savings in a population of anemic patients with lymphoid malignancies not receiving chemotherapy Blood 2007 abstract 5179","DOI":"10.1182\/blood.V110.11.5179.5179"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients","volume":"92","author":"Hellstr\u00f6m Lindberg","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0170|cit170","doi-asserted-by":"crossref","unstructured":"Henry DH Dahl NV Auerbach M Tchekmedyian S Laufman LR Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy results of a multicenter, randomized trial Blood 2004 10b, abstract 3696","DOI":"10.1182\/blood.V104.11.3696.3696"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1185\/030079906X115559","article-title":"Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia","volume":"22","author":"Henry","year":"2006","journal-title":"Current Medical Research & Opinion"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007303.pub2-BIB0172|cit172","first-page":"16","article-title":"Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U every two weeks) versus weekly dosing (40,000 U weekly) in anemic patients with cancer receiving chemotherapy","volume":"5","author":"Henry","year":"2007","journal-title":"Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0174|cit173","doi-asserted-by":"crossref","unstructured":"Henry DH Dahl NV Auerbach M Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis? Blood 2007 abstract 1625","DOI":"10.1182\/blood.V110.11.1625.1625"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0173|cit174","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0175|cit175","unstructured":"Henze G Michon J Morland B Perek D Rizzari C Zoubek A Phase III randomized study: efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy Proceedings of the American Society of Clinical Oncology 2002 abstract 1547"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.11954","article-title":"A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies","volume":"100","author":"Hesketh","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0177|cit177","unstructured":"Hesketh PJ Arena F Patel D Poulsen E D'Avirro P Rossi G Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles Proceedings of the American Society of Clinical Oncology 2003 abstract 2941"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0885-3924(03)00070-8","article-title":"Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial","volume":"25","author":"Iconomou","year":"2003","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Italian Cooperative Study Group","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0180|cit180","unstructured":"Janinis J Dafni U Aravantinos G Kalofonos HP Papakostas P Tsavdaridis D Quality of life (QoL) outcome of epoietin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by the Hellenic Cooperative Oncology Group Proceedings of the American Society of Clinical Oncology 2003 789"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0181|cit181","first-page":"283","article-title":"Impact of therapy with recombinant human erythropoietin (r-HuEPO) and Quality-of-life in anemic cancer patients","volume":"17","author":"Jitnuyanont","year":"2001","journal-title":"Internal Medicine Journal of Thailand"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/003655901750425864","article-title":"Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer - a randomized study","volume":"35","author":"Johansson","year":"2001","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdi218","article-title":"A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"16","author":"Justice","year":"2005","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2168.1998.00564.x","article-title":"Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma","volume":"85","author":"Kettelhack","year":"1998","journal-title":"British Journal of Surgery"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.SLA.0000055275.38740.56","article-title":"Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study","volume":"237","author":"Kosmadakis","year":"2003","journal-title":"Annals of Surgery"},{"issue":"11","key":"10.1002\/14651858.CD007303.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"abstract 1636","DOI":"10.1182\/blood.V104.11.1636.1636","article-title":"Correction\/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial","volume":"104","author":"Kotasek","year":"2004","journal-title":"Blood"},{"issue":"2 SUPPL. 1","key":"10.1002\/14651858.CD007303.pub2-BIB0187|cit187","first-page":"16","article-title":"Correction\/maintenance dosing (front loading) of darbepoetin alfa: Final results from a randomized phase III active-controlled trial","volume":"3","author":"Kotasek","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1185\/030079907X188053","article-title":"A randomized, controlled trial comparing darbepoetin alfa correction\/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia","volume":"23","author":"Kotasek","year":"2007","journal-title":"Current Medical Research & Opinion"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10147-001-8031-y","article-title":"Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer","volume":"6","author":"Kunikane","year":"2001","journal-title":"International Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/gyno.1997.4675","article-title":"Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study","volume":"65","author":"Kurz","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0191|cit191","first-page":"177","article-title":"Erythropoietin and cisplatin-induced neuropathies in cancer patients","volume":"153","author":"Mangiameli","year":"2002","journal-title":"Clinica Terapeutica"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0192|cit192","first-page":"486","article-title":"Pretreatment normalization of mild anemia with epoetin alfa: Impact on the outcome in epithelial ovarian cancer patients","volume":"22","author":"Marinaccio","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0193|cit193","doi-asserted-by":"crossref","unstructured":"Merlano M Ricci S Martoni A Comparing the efficacy of fixed vs. weight-based dosing of epoetin alfa in anemic cancer patients receiving platinum-based chemotherapy European Journal of Cancer 2001 S346","DOI":"10.1016\/S0959-8049(01)81776-7"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0194|cit194","unstructured":"Luksenburg H Weir A Wager R MF4266 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0195|cit195","doi-asserted-by":"crossref","unstructured":"Miller KB Kim HT Greenberg P van der Jagt R Bennett JM Tallman MS Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): Results of the ECOG-CLSG trial (E1996) Blood 2004 70","DOI":"10.1182\/blood.V104.11.70.70"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jjco\/hyl097","article-title":"Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study","volume":"36","author":"Morishima","year":"2006","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0197|cit197","first-page":"3495","article-title":"Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment","volume":"25","author":"Mystakidou","year":"2005","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/02841860214960","article-title":"Erythropoietin treatment in metastatic breast cancer - effects on Hb, quality of life and need for transfusion","volume":"41","author":"Olsson","year":"2002","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0200|cit199","unstructured":"Overgaard J Interim Analysis of DAHANCA 10 http:\/\/www.dahanca.dk\/get_media_file.php?mediaid=125 [accessed April 1, 2009]"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0199|cit200","doi-asserted-by":"crossref","unstructured":"Overgaard J Hoff C Sand Hansen H Specht L Overgaard M Grau C Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp\u00ae) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial European Journal of Cancer Supplements 2007 abstract 6LB","DOI":"10.1016\/S1359-6349(07)70099-X"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.1999.17.4.1288","article-title":"Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubucin, Paclitaxel and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison","volume":"17","author":"Pierelli","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1548-5315(11)70071-7","article-title":"Epoetin alfa for chemotherapy-induced anemia: Assessment of two equivalent dosing regimens","volume":"4","author":"Policarpo","year":"2007","journal-title":"Community Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0022-3476(96)70145-2","article-title":"Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial","volume":"129","author":"Porter","year":"1996","journal-title":"Journal of Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0959-8049(98)00021-5","article-title":"Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO)","volume":"34","author":"Rau","year":"1998","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0205|cit205","doi-asserted-by":"crossref","unstructured":"Charu V Saidman B Ben-Jacob A Justice GR Maniam AS Rearden T Improvements in fatigue are associated with early treatment with darbepoetin alfa every 3 weeks (Q3W) Darbepoetin alfa (DA) Treatment in Anemic Patients (pts) Receiving Chemotherapy Blood 2004 abstract 233","DOI":"10.1182\/blood.V104.11.233.233"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0206|cit206","doi-asserted-by":"crossref","unstructured":"Rearden T Charu V Saidman B Justice GR Manaim AS Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA) Blood 2003 abstract 3783","DOI":"10.1200\/jco.2004.22.90140.8064"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD007303.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"abstract 8064","DOI":"10.1200\/jco.2004.22.90140.8064","article-title":"Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA)","volume":"22","author":"Rearden","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1185\/030079905X65394","article-title":"Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia","volume":"21","author":"Reed","year":"2005","journal-title":"Current Medical Research & Opinion"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0209|cit209","unstructured":"Rosen FR Haraf D Brockstein B Multicenter randomized phase II study of 1 hour infusion paclitaxel, fluorouracil and hydroxyurea with concomitant hyperfractionated radiotherapy with or without erythropoietin for advanced head and neck cancer Proceedings of the American Society of Clinical Oncology 2001 abstract 902"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0210|cit210","first-page":"1689","article-title":"Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer","volume":"9","author":"Rosen","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpainsymman.2003.06.010","article-title":"The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events","volume":"27","author":"Rosenzweig","year":"2004","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0212|cit212","unstructured":"Rubio-Martinez A Recas\u00e9ns V Mayayo P Montanes A Rubio-F\u00e9lix D Giraldo P Anaemia associated to multiple myeloma: response to epoetin alpha Hematology Journal 2003 S202, abstract 258"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0213|cit213","doi-asserted-by":"crossref","unstructured":"Sakai H Saijo N Ohashi Y Once-weekly epoetin beta improves hemoglobin levels and quality of life in patients with chemotherapy-induced anemia:A randomized, double blind, parallel group dose finding study Annals of Oncology 2004","DOI":"10.1200\/jco.2004.22.90140.8169"},{"issue":"Suppl","key":"10.1002\/14651858.CD007303.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"abstract 8169","DOI":"10.1200\/jco.2004.22.90140.8169","article-title":"Once-weekly epoetin beta improves hemoglobin levels and quality of life in patients with chemotherapy-induced anemia:A randomized, double blind, parallel group dose finding study","volume":"22","author":"Sakai","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.9-6-696","article-title":"A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer","volume":"9","author":"Schwartzberg","year":"2004","journal-title":"Oncologist"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007303.pub2-BIB0216|cit216","first-page":"30","article-title":"Comparable efficacy and safety of darbepoetin alfa 200 mug every 2 weeks and epoetin alfa 40,000 U weekly in patients with breast cancer: Results of a randomized comparison","volume":"3","author":"Schwartzberg","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007303.pub2-BIB0217|cit217","first-page":"22","article-title":"A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia","volume":"5","author":"Schwartzberg","year":"2007","journal-title":"Journal of Supportive Oncology"},{"issue":"7 Pt 1","key":"10.1002\/14651858.CD007303.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/00005537-200207000-00015","article-title":"The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study","volume":"112","author":"Scott","year":"2002","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3816\/CBC.2005.n.050","article-title":"Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly","volume":"6","author":"Senecal","year":"2005","journal-title":"Clinical Breast Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/14737167.7.2.187","article-title":"Impact of dose frequency on compliance and health outcomes: A literature review (1966-2006)","volume":"7","author":"Shi","year":"2007","journal-title":"Expert Review of Pharmacoeconomics and Outcomes Research"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","article-title":"Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma","volume":"70","author":"Silvestris","year":"1995","journal-title":"Annals of Hematology"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","article-title":"A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer","volume":"88","author":"Smith","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0223|cit223","unstructured":"Spicka I Beguin Y Effect of anemia correction with epoetin beta (neorecormon) once weekly on performance status and disease response Hematology Journal 2004 abstract 553"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2005.02.7276","article-title":"Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer","volume":"24","author":"Steensma","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0225|cit225","doi-asserted-by":"crossref","unstructured":"Steensma DP Molina R Sloan JA Nikcevich DA Schaefer Pl Rowland KM A Phase III Randomized Trial of Two Different Dosing Schedulesof Erythropoietin (EPO) in Patients With Cancer-Associated Anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2 Journal of Clinical Oncology abstract 8031","DOI":"10.1200\/jco.2005.23.16_suppl.8031"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V78.7.1658.1658","article-title":"Pharmacologic Doses of Recombinant Human Erythropoietin in the Treatment of Myelodysplastic Syndromes","volume":"78","author":"Stein","year":"1991","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0227|cit227","unstructured":"Straus DJ Testa M Riggs SA Tulpule A Sarokhan B Early treatment with epoetin alfa improves anemia, quality of life, and productivity in patients with hematologic malignancies and mild anemia during chemotherapy Blood 2003 abstract 1811"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.22221","article-title":"Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies","volume":"107","author":"Straus","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1002\/14651858.CD007303.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/bjc.1998.331","article-title":"Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labeled, phase II trial","volume":"77","author":"Sweeney","year":"1998","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","article-title":"Effect of recombinant human erythropoietin combined with granulocyte\/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome","volume":"95","author":"Thompson","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0231|cit231","unstructured":"Throuvalas NA Antonadou D Boufi M Lavey R Erythropoietin decreases Transfusion Requirements during Radiochemotherapy Proceedings of the American Society of Clinical Oncology 2000 abstract 1558"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1007951530405","article-title":"Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia","volume":"11","author":"Tsukuda","year":"1998","journal-title":"Biotherapy"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mpo.10185","article-title":"Is epoetin alfa a treatment option for chemotherapy-related anemia in children?","volume":"39","author":"Buyukpamukcu","year":"2002","journal-title":"Medical and pediatric oncology"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1542\/peds.103.2.e16","article-title":"Recombinant human erythropoietin treatment for chemotherapy-related anemia in children","volume":"103","author":"Varan","year":"1999","journal-title":"Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.2004.01.002","article-title":"Combined use of erythropoietin and granulocyte colony- stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: A randomized controlled trial","volume":"22","author":"Wagner","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1634\/theoncologist.10-8-642","article-title":"Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy","volume":"10","author":"Waltzman","year":"2005","journal-title":"The oncologist"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0237|cit237","doi-asserted-by":"crossref","unstructured":"Waltzman R Williams D Head-To-Head Comparison of Epoetin Alfa (EPO) 40,000 QW vs Darbepoetin Alfa (DARB) 200 \u00b5g Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA) Blood 2004 abstract 4233","DOI":"10.1182\/blood.V104.11.4233.4233"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0239|cit238","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/cncr.20116","article-title":"A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease","volume":"100","author":"Waltzman","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0238|cit239","doi-asserted-by":"crossref","unstructured":"Waltzman RJ Croot C Williams D Final haematologic results: epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 \u00b5g Q2W in anemic cancer patients (pts) receiving chemotherapy (CT) Journal of Clinical Oncology 2005 abstract 8030","DOI":"10.1200\/jco.2005.23.16_suppl.8030"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0240|cit240","unstructured":"Watanabe M Ezaki K Tobinai K Tsuboi M Ohashi Y Hirashima K A multicenter phase III randomized, double-blind placebo-controlled study of Epoetin beta administered once-weekly for chemotherapy induced anemia (CIA) in cancer patients: Japan Erythropoietin Study Group Annals of Oncology 2006 294"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0241|cit241","first-page":"261","article-title":"Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer","volume":"1","author":"Welch","year":"1995","journal-title":"Cancer Journal of the Scientific American"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1537-2995.1996.36296181929.x","article-title":"Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)","volume":"36","author":"Wurnig","year":"1996","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/pho.21.1.1.8","article-title":"A single institutional experience: is epoetin alpha effective in anemic children with cancer?","volume":"21","author":"Yilmaz","year":"2004","journal-title":"Pediatric Hematology and Oncology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007303.pub2-BIB0244|cit244","first-page":"abstract 0177","article-title":"An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-containing chemotherapy","volume":"61","author":"Zagari","year":"2003","journal-title":"The Hematology Journal"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0245|cit245","doi-asserted-by":"crossref","unstructured":"Zajda K Krzakowski M Epoetin delta in the management of anaemia in cancer patients Journal of Clinical Oncology 2007 abstract 19555","DOI":"10.1200\/jco.2007.25.18_suppl.19555"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0246|cit246","first-page":"861","article-title":"Clinical observations on RHuEPO in the treatment of breast cancer chemotherapy related anemia","volume":"10","author":"Zhang","year":"2003","journal-title":"China Journal of Cancer Prevention and Treatment"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0247|cit247","first-page":"355","article-title":"Clinical observation of recombinant human erythropoietin in treatment of preoperative anemia in patients with gastric cancer","volume":"6","author":"Zhou","year":"2006","journal-title":"Pharmaceutical Care & Research (Yaoxue Fuwu Yu Yanjiu)"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Transactions on Automatic Control"},{"issue":"7168","key":"10.1002\/14651858.CD007303.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"issue":"7223","key":"10.1002\/14651858.CD007303.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0006-291X(03)01303-2","article-title":"Expression of erythropoietin receptor splice variants in human cancer","volume":"307","author":"Arcasoy","year":"2003","journal-title":"Biochemical Biophysical Research Communications"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.3800288","article-title":"Erythropoietin and erythropoietin receptor expression in human prostate cancer","volume":"18","author":"Arcasoy","year":"2005","journal-title":"Modern Pathology"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1002\/14651858.CD007303.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"3. Art.No.: CD0","key":"10.1002\/14651858.CD007303.pub2-BIB0255|cit255","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003407.pub2","article-title":"Erythropoietin for patients with malignant disease","author":"Bohlius","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/dji087","article-title":"Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis","volume":"97","author":"Bohlius","year":"2005","journal-title":"Journal of the National Cancer Institut"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"Journal of the National Cancer Institut"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(02)00677-0","article-title":"Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?","volume":"3","author":"Bottomley","year":"2002","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0895-4356(98)00129-2","article-title":"Statistical methods in epidemiology: a comparison of statistical methods to analyze dose-response and trend analysis in epidemiologic studies","volume":"51","author":"Boucher","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0260|cit260","doi-asserted-by":"crossref","unstructured":"Brines ML Ghezzi P Keenan S Agnello D de Lanerolle NC Cerami C Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury Proceedings of National Academy of Sciences of the United States of America 2000 10526 31","DOI":"10.1073\/pnas.97.19.10526"},{"issue":"41","key":"10.1002\/14651858.CD007303.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proceedings of Natiional Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007303.pub2-BIB0263|cit263","first-page":"13","article-title":"The functional assessment of cancer therapy-anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue","volume":"34","author":"Cella","year":"1997","journal-title":"Seminars in Hematology"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2407-2-23","article-title":"Erythropoietin, uncertainty principle and cancer related anaemia","volume":"2","author":"Clark","year":"2002","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMoa071533","article-title":"Efficacy and safety of epoetin alfa in critically ill patients","volume":"357","author":"Corwin","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"2, CD006145. DO","key":"10.1002\/14651858.CD007303.pub2-BIB0266|cit266","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006145.pub2","article-title":"Exercise for the management of cancer-related fatigue in adults","author":"Cramp","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(89)90965-3","article-title":"Expression cloning of the murine erythropoietin receptor","volume":"57","author":"D'Andrea","year":"1989","journal-title":"Cell"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.993.11.3","article-title":"Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas","volume":"11","author":"Dagnon","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0270|cit270","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/9780470693926.ch1","article-title":"Rationale, potentials, and promise of systematic reviews","volume-title":"Systematic reviews in health care: meta-analysis in context.","author":"Egger","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ahj.2004.04.049","article-title":"Reducing the costs of phase III cardiovascular clinical trials","volume":"149","author":"Eisenstein","year":"2005","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2005-10-4066","article-title":"Anti-Epo receptor antibodies do not predict Epo receptor expression","volume":"107","author":"Elliott","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pros.20310","article-title":"Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells","volume":"66","author":"Feldman","year":"2006","journal-title":"Prostate"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/153537020322800101","article-title":"Erythropoietin: physiology and pharmacology update","volume":"228","author":"Fisher","year":"2003","journal-title":"Experimental Biology and Medicine (Maywood)"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-995829","article-title":"Hemostasis and malignancy","volume":"24","author":"Francis","year":"1998","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD007303.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.CCM.0000100124.50579.D9","article-title":"Risks of blood transfusion","volume":"31","author":"Goodnough","year":"2003","journal-title":"Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.atc.2004.07.004","article-title":"Risks of blood transfusion","volume":"23","author":"Goodnough","year":"2005","journal-title":"Anesthesiology Clinics of North America"},{"issue":"19","key":"10.1002\/14651858.CD007303.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"Journal of the National Cancer Institut"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.1991.210","article-title":"Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta","volume":"50","author":"Halstenson","year":"1991","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1371\/journal.pone.0000549","article-title":"Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression","volume":"2","author":"Hardee","year":"2007","journal-title":"PLoS ONE"},{"issue":"29","key":"10.1002\/14651858.CD007303.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2006.06.2737","article-title":"Do erythropoietin receptors on cancer cells explain unexpected clinical findings?","volume":"24","author":"Henke","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD007303.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0284|cit284","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4","author":"Higgins","year":"2006"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0167-8140(93)90025-4","article-title":"Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix","volume":"26","author":"Hockel","year":"1993","journal-title":"Radiotherapy Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdf122","article-title":"The impact of hemoglobin levels on fatigue and quality of life in cancer patients","volume":"13","author":"Holzner","year":"2002","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2008.03.006","article-title":"The erythropoietin receptor in normal and cancer tissues","volume":"67","author":"Jelkmann","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood.V71.2.524.524","article-title":"Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization","volume":"71","author":"Koury","year":"1988","journal-title":"Blood"},{"issue":"4953","key":"10.1002\/14651858.CD007303.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1126\/science.2326648","article-title":"Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells","volume":"248","author":"Koury","year":"1990","journal-title":"Science"},{"issue":"11","key":"10.1002\/14651858.CD007303.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood.V77.11.2497.2497","article-title":"Localization of cells producing erythropoietin in murine liver by in situ hybridization","volume":"77","author":"Koury","year":"1991","journal-title":"Blood"},{"issue":"261 (7)","key":"10.1002\/14651858.CD007303.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/S0021-9258(17)35756-3","article-title":"Structural characterization of human erythropoietin","volume":"5","author":"Lai","year":"1986 March","journal-title":"Journal of Biological Chemistry"},{"issue":"2. Art. No.: CD","key":"10.1002\/14651858.CD007303.pub2-BIB0292|cit292","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003407","article-title":"Erythropoietin for patients with malignant disease","author":"Langensiepen","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD007303.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1158\/1078-0432.CCR-06-1285","article-title":"Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis","volume":"12","author":"Leo","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1046\/j.1538-7836.2003.00275.x","article-title":"From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer","volume":"1","author":"Levine","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1002\/14651858.CD007303.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.bjc.6600247","article-title":"The level of haemoglobin in anaemic cancer patients correlates positively with quality of life","volume":"86","author":"Lind","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.8-1-99","article-title":"Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients","volume":"8","author":"Littlewood","year":"2003","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0297|cit297","unstructured":"Ludwig H Strasser K Symptomatology of anemia Seminars in Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007303.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0299|cit299","unstructured":"Luksenburg H Weir A Wager R Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the treatment of anemia associated with cancer chemotherapy Hearings before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville (MD), USA, 2004"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2005.06.038","article-title":"Erythropoietin receptor function and expression in epithelial ovarian carcinoma","volume":"99","author":"McBroom","year":"2005","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/009286159903300113","article-title":"Checks of case record forms versus the database for efficacy variables when validation programs exist","volume":"33","author":"Mcentegart","year":"1999","journal-title":"Drug Information Journal"},{"issue":"16","key":"10.1002\/14651858.CD007303.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jnci\/djn250","article-title":"A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue","volume":"100","author":"Minton","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1593\/neo.04685","article-title":"Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma","volume":"7","author":"Mohyeldin","year":"2005","journal-title":"Neoplasia"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejca.2006.10.012","article-title":"Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia","volume":"43","author":"Osterborg","year":"2007","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11060-006-9289-8","article-title":"Schwann cells in neuroblastoma express erythropoietin","volume":"82","author":"Ribatti","year":"2007","journal-title":"Journal of Neuro-Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2559.2007.02653.x","article-title":"Erythropoietin\/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma","volume":"50","author":"Ribatti","year":"2007","journal-title":"Histopathology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of Epoetin and Darbepoetin in Patients with Cancer. American Society of Clinical Oncology\/American Society of Hematology Clinical Practice Guideline Update","volume":"26","author":"Rizzo","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/ije\/28.5.964","article-title":"The use of fractional polynomials to model continuous risk variables in epidemiology","volume":"28","author":"Royston","year":"1999","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD007303.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00001813-199902000-00002","article-title":"Role of red blood cells in pharmacokinetics of chemotherapeutic agents","volume":"10","author":"Schrijvers","journal-title":"Anticancer Drugs"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0310|cit310","doi-asserted-by":"crossref","unstructured":"Sehata N Walker I Meyer R Haynes AE Imrie K and Cancer Care Ontario's Program in Evidence-Based Care's Systematic Disease Site Group Treatment for anemia with erythropoietic agents in patients with non-myeloid hematological malignancies: a clinical practice guideline Report 2007 6 12","DOI":"10.1007\/s00277-008-0525-5"},{"issue":"16","key":"10.1002\/14651858.CD007303.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/93.16.1204","article-title":"Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta analysis of controlled clinical trials","volume":"93","author":"Seidenfeld","year":"2001","journal-title":"Journal of the National Cancer Institut"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0312|cit312","unstructured":"Seidenfeld J Piper M Bohlius J Weingart O Trelle S Engert A Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment Comparative Effectiveness, Review No. 3, Rockville, MD: Agency for Healthcare Research and Quality, May 2006"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1191\/1740774505cn087oa","article-title":"Meta-analysis of individual patient data from randomized trials: a review of methods used in practice","volume":"2","author":"Simmonds","year":"2005","journal-title":"Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD007303.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bjc.6604220","article-title":"Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells","volume":"98","author":"Sinclair","year":"2008","journal-title":"British Journal of Cancer"},{"issue":"20","key":"10.1002\/14651858.CD007303.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007303.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/sim.2050","article-title":"Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes","volume":"24","author":"Smith","year":"2005","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1740774507085276","article-title":"A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes","volume":"4","author":"Smith","year":"2007","journal-title":"Clinical Trials"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc1648","article-title":"The anaemia of cancer: death by a thousand cuts","volume":"5","author":"Spivak","year":"2005","journal-title":"Nature Reviews Cancer"},{"issue":"10","key":"10.1002\/14651858.CD007303.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"issue":"19","key":"10.1002\/14651858.CD007303.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/sim.4780141902","article-title":"Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group","volume":"14","author":"Stewart","year":"1995","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007303.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V95.9.2983.009k27_2983_2989","article-title":"Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans","volume":"95","author":"Stohlawetz","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.1998.00521.x","article-title":"Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties","volume":"100","author":"Storring","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.CCM.0000159849.94750.51","article-title":"Transfusion-related acute lung injury: definition and review","volume":"33","author":"Toy","year":"2005 April","journal-title":"Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007303.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cellsig.2006.08.014","article-title":"A \"classical\" homodimeric erythropoietin receptor is essential for the anti-apoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells","volume":"19","author":"Um","year":"2007","journal-title":"Cell Signal"},{"issue":"4","key":"10.1002\/14651858.CD007303.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1385\/MO:18:4:243","article-title":"Treatment resistance of solid tumors: role of hypoxia and anemia","volume":"18","author":"Vaupel","year":"2001","journal-title":"Medical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007303.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00066-002-1081-x","article-title":"Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?","volume":"178","author":"Vaupel","year":"2002","journal-title":"Strahlentherapie und Onkologie"},{"issue":"1","key":"10.1002\/14651858.CD007303.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tracli.2004.11.005","article-title":"Hypoxia and anemia: effects on tumor biology and treatment resistance","volume":"12","author":"Vaupel","year":"2005","journal-title":"Transfusion Clinique et Biologique"},{"issue":"5","key":"10.1002\/14651858.CD007303.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension","volume":"33","author":"Vaziri","year":"1999","journal-title":"American Journal of Kidney Diseases"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD007303.pub2-BIB0329|cit329","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tri part assessment survey. The Fatigue Coalition","volume":"34","author":"Vogelzang","year":"1997","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/0470854200.ch5","article-title":"Meta-analysis using individual patient data","volume-title":"Meta-Analysis of Controlled Clinical Trials","author":"Whitehead","year":"2002"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11130","article-title":"A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment","volume":"11","author":"Wilson","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI117840","article-title":"Cisplatin-associated anemia: an erythropoietin deficiency syndrome","volume":"95","author":"Wood","year":"1995","journal-title":"Journal of Clinical Investigation"},{"issue":"7","key":"10.1002\/14651858.CD007303.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/cncr.11700","article-title":"Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin","volume":"98","author":"Wun","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD007303.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/carcin\/bgg060","article-title":"Erythropoietin regulates tumour growth of human malignancies","volume":"24","author":"Yasuda","year":"2003","journal-title":"Carcinogenesis"},{"issue":"3. Art. No.: CD","key":"10.1002\/14651858.CD007303.pub2-BIB0335|cit335","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007303","article-title":"Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data.","author":"Bohlius","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9674","key":"10.1002\/14651858.CD007303.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007303.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:05:07Z","timestamp":1769990707000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007303.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":336,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2010,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007303.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]}}}